Skip to main content
. 2022 Mar 8;22:79. doi: 10.1186/s12883-022-02588-3

Table 1.

Characteristics of patients included according to TyG index quartiles

Characteristics Quartiles of the TyG index P value
Quartiles 1,
4.31–5.48
Quartiles 2,
5.48–5.81
Quartiles 3,
5.81–6.22
Quartiles 4,
6.22–8.17
Patients, n (%) 306 307 307 306
Male, n (%) 197(64.8) 182(59.5) 191(62.2) 202(66.7) 0.28
Age, y, median (IQR) 67.0(55.0–75.0) 65.0(53.0–75.0) 60.0(53.0–69.0) 59.0(51.0–70.0)  < 0.001
BMI, median (IQR) 24.0(21.6–26.2) 24.9(22.5–27.0) 24.9(22.9–27.3) 25.2(23.4–27.4)  < 0.001
Smoking, n (%) 0.49
 Current smoker 99(32.4) 93(30.3) 99(32.2) 114(37.3)
 Ever smoker 31(10.1) 26(8.5) 34(11.1) 30(9.8)
 Nonsmoker 176(57.5) 188(61.2) 174(56.7) 162(52.9)
Medical history
 Hypertension, n (%) 161 (52.6) 174(56.7) 198(64.5) 203(66.3) 0.001
 Hyperlipidemia, n (%) 20(6.5) 28(9.1) 43(14.0) 50(16.3)  < 0.001
 Atrial fibrillation, n (%) 34(11.1) 17(5.5) 14(4.6) 10(3.3)  < 0.001
 Coronary heart disease, n (%) 32(10.5) 39(12.7) 39(12.7) 38(12.4) 0.80
Medication during hospitalization, n (%)
 Antihypertensive drugs 118(38.6) 136(44.3) 145(47.2) 144(47.1) 0.11
 Statins 156(51.0) 138(45.0) 157(51.1) 176(57.5) 0.02
 Intravenous alteplase 8(2.6) 7(2.3) 9(2.9) 12(3.9) 0.66
 Antiplatelet 194(63.4) 187(60.9) 188(61.2) 194(63.4) 0.87
 Anticoagulation 25(8.2) 22(7.2) 15(4.9) 18(5.9) 0.37
Complications during hospitalization, n (%)
 Pulmonary infection 29(9.5) 36(11.7) 21(6.8) 9(2.9)  < 0.001
 Urinary infection 6(2.0) 18(5.9) 11(3.6) 7(2.3) 0.03
 NIHSS at admission, median (IQR) 4(2–8) 5(3–9) 4(2–8) 4(2–6)  < 0.001
TOAST subtypes, n (%) 0.04
 Large artery atherosclerosis 184(60.1) 194(63.2) 188(61.2) 185(60.5)
 Small artery occlusion 74(24.2) 72(23.5) 87(28.3) 90(29.4)
 Cardioembolism 30(9.8) 22(7.2) 18(5.9) 7(2.3)
 Other/undetermined 6(2.0) 9(2.9) 5(1.6) 12(3.9)
 Undefined 12(3.9) 10(3.3) 9(2.9) 12(3.9)

Abbreviations: TyG index indicates triglyceride glucose index, BMI Body mass index, IQR interquartile range, NIHSS National Institutes of Health Stroke Scale, TOAST Trial of Org 10,172 in Acute Stroke Treatment